Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer."

被引：0
|
作者：
Apsey, H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Roy, V. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Pockaj, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Northfelt, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sticca, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Nikcevich, D. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Mattar, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Fitch, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Perez, E. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Mayo Clin Arizona, Phoenix, AZ USA
[2] Mayo Clin Minnesota, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Univ N Dakota, Grand Forks, ND 58201 USA
[5] Duluth Clin, Duluth, MN USA
[6] Wichita Community Clin Oncol Program, Wichita, KS USA
[7] Mayo Clin Florida, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
623
引用
收藏
页数：2
相关论文
共 50 条
  • [1] N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer
    Roy, V.
    Pockaj, B. A.
    Northfelt, D. W.
    Allred, J. B.
    Liu, H.
    Nikcevich, D. A.
    Mattar, B. I.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast Cancer NCCTG Study N0338
    Roy, Vivek
    Pockaj, Barbara A.
    Allred, Jacob B.
    Apsey, Heidi
    Northfelt, Donald W.
    Nikcevich, Daniel
    Mattar, Bassam
    Perez, Edith A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (06): : 540 - 544
  • [3] NCCTG N0338: effect of docetaxel and carboplatin on VEGF, PGE2, and immune cells in patients with stage II or III breast cancer.
    Pockaj, B. A.
    Mukherjee, P.
    Tinder, T. L.
    Klosterman, C. A.
    Allerd, J. B.
    Roy, V
    Perez, E. A.
    CANCER RESEARCH, 2009, 69 (02) : 333S - 334S
  • [4] Phase II study of neoadjuvant dose-dense docetaxel in stage II/III breast cancer.
    Chakravarthy, B.
    Mayer, I. A.
    Meszoely, I
    Means-Powell, J.
    Kelley, M. C.
    Grau, A.
    Johnson, D. H.
    McLaren, B. N.
    Broome, E. E.
    Pietenpol, J. A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S148 - S148
  • [5] Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel Followed by Epirubicin in Stage II/III Breast Cancer
    Bhuvaneswari Ramaswamy
    Steven P Povoski
    Chris Rhoades
    Joan Allen
    Marsha Hauger
    Donn Young
    William Burak
    William Farrar
    Lisa Yee
    Kari Kendra
    Sivagurunathan Somasundaram
    Robert Z Orlowski
    Charles L. Shapiro
    Breast Cancer Research and Treatment, 2005, 93 : 67 - 74
  • [6] Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer
    Ramaswamy, B
    Povoski, SP
    Rhoades, C
    Allen, J
    Hauger, M
    Young, D
    Burak, W
    Farrar, W
    Yee, L
    Kendra, K
    Somasundaram, S
    Orlowski, RZ
    Shapiro, CL
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 93 (01) : 67 - 74
  • [7] Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer:: Preliminary results of a phase II trial
    Colomer, R
    Llombart, A
    Lluch, A
    Ojeda, B
    Barnadas, A
    Carañana, V
    Fernández, Y
    De Paz, L
    Guillem, V
    Alonso, S
    SEMINARS IN ONCOLOGY, 2000, 27 (01) : 20 - 24
  • [8] A phase II randomized study to compare the neoadjuvant administration of docetaxel and vinorelbine or docetaxel followed by adriamycin and cytoxan with all chemotherapy administered in a dose dense fashion to women with stage II and stage III breast cancer.
    Limentani, SA
    Brufsky, AM
    Rubin, P
    Lambert-Falls, R
    Carroll, M
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S225 - S225
  • [9] Weekly docetaxel as neoadjuvant treatment in stage II and III breast cancer.: Final results of a phase II, multicenter GEICAM study
    Gacia-Estévez, L
    Cuevas, J
    Antón, A
    Florián, J
    López-Vega, J
    Velasco, A
    Lobo, F
    Fortes, J
    Díaz, FJ
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S65 - S65
  • [10] Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer.
    Burdette-Radoux, S
    Wood, ME
    Olin, JJ
    Broom, R
    Crocker, A
    Ashikaga, T
    Muss, HB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 81S - 81S
12345